ArticleCNS neuroscience & therapeutics2025
Factors Influencing Hormone Remission in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors With Residual Tumor: A Retrospective Cohort Study.
Article in CNS neuroscience & therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Postoperative Pituitary MRI Findings in Acromegaly: A Pictorial Review.Diagnostics (Basel, Switzerland) · 2026Review
- An MRI radiomics approach using invasion-based weak supervision for identifying and evaluating aggressive PitNETs.NPJ digital medicine · 2025Article
- Factors Influencing Hormone Remission in Growth Hormone-Secreting Pituitary Neuroendocrine Tumors With Residual Tumor: A Retrospective Cohort Study.CNS neuroscience & therapeutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundGrowth hormone-secreting pituitary neuroendocrine tumors (GH-secreting PitNETs) pose significant health risks due to hormone-related complications. Despite transsphenoidal surgical resection being the primary treatment, complete removal is often infeasible due to invasive growth patterns, leading to postoperative tumor residuals and uncertain hormone remission outcomes.
methodsThis retrospective study included 458 patients with GH-secreting PitNETs who underwent surgery at Beijing Tiantan Hospital. Data on preoperative hormone levels, MRI scans, and histopathological features were analyzed. Tumor segmentation, intratumor heterogeneity (ITH) scores, and subcluster clustering based on MRI data were computed using radiomic features, while multivariate analyses determined factors influencing hormone remission. Single-cell data from four GH-type pituitary adenomas were collected from public databases to explore ITH in GH1 gene expression.
resultsPostoperative hormone remission was achieved in 61 of 144 patients (42.4%) with residual tumors. Univariate analysis demonstrated that in cases with tumor residuals, preoperative hormone levels, tumor resection rates, residual tumor volume, tumor residual location, residual-tumor proximity to the internal carotid artery, and MRI-based tumor heterogeneity were associated with hormone remission. Among these factors, preoperative hormone levels (10-30 ng/mL vs. ≤ 10 ng/mL: OR: 0.48, 95% CI 0.20-1.19, p = 0.115; > 30 ng/mL vs. ≤ 10 ng/mL: OR: 0.13, 95% CI: 0.04-0.36, p < 0.001), tumor resection rate (OR: 18.29, 95% CI: 2.08-160.97, p = 0.009), and tumor heterogeneity as measured by the ITH score (OR: 1.06, 95% CI: 1.00-1.12, p = 0.042) were independent predictors of hormone remission in cases with residual tumors. Moreover, single-cell data showing highly variable GH1 expression within the same patient reveal ITH in hormone expression.
conclusionPreoperative GH levels, tumor resection rates, and ITH scores independently predict hormone remission in GH-secreting PitNETs with residuals. This will provide intraoperative decision-making guidance on how to achieve the maximum possible hormone remission with residual tumors when complete tumor resection is not feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.